Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Net Income Loss of -$124.02 million for the year ending 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +4.6% in Net Income Loss from 2024 to 2025.
- This data is from Tonix Pharmaceuticals Holding Corp.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), Tonix Pharmaceuticals Holding Corp.'s Net Income Loss has declined by 61,296.5%.
- Historical annual values: Fiscal year 2025: -$124.02 million | Fiscal year 2024: -$130.04 million | Fiscal year 2023: -$116.66 million | Fiscal year 2022: -$110.22 million | Fiscal year 2021: -$92.29 million | Fiscal year 2020: -$50.46 million | Fiscal year 2019: -$28.62 million | Fiscal year 2018: -$26.09 million | Fiscal year 2017: -$21.12 million | Fiscal year 2016: -$38.84 million | Fiscal year 2015: -$48.05 million | Fiscal year 2014: -$27.62 million | Fiscal year 2013: -$10.88 million | Fiscal year 2012: -$9.45 million | Fiscal year 2011: -$3.47 million | Fiscal year 2010: -$1.96 million | Fiscal year 2009: -$221.0 thousand | Fiscal year 2008: -$202.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: